Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00392444 · BASELINE

Baseline characteristics

Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma · Source last updated 2014-05-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      35
    units
    Participants
groups
  1. description
    Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
    id
    BG000
    title
    Treatment (Sunitinib Malate)
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          48
          upper Limit
          79
          value
          66
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          6
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          29
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          35
      title
      Canada
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
population Description
1 patient was cancelled due to intercurrent illness and another 3 were found to be ineligible after review. Those 4 patients were excluded from all analyses.
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      35
    units
    Participants
groups
  1. description
    Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
    id
    BG000
    title
    Treatment (Sunitinib Malate)
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          48
          upper Limit
          79
          value
          66
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          6
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          29
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          35
      title
      Canada
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
population Description
1 patient was cancelled due to intercurrent illness and another 3 were found to be ineligible after review. Those 4 patients were excluded from all analyses.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice